Weekly Research Analysts’ Ratings Changes for Septerna (SEPN)

Several brokerages have updated their recommendations and price targets on shares of Septerna (NASDAQ: SEPN) in the last few weeks:

• 8/12/2026 – Septerna had its price target raised by Wells Fargo & Company from $48.00 to $50.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Septerna had its price target raised by HC Wainwright from $40.00 to $60.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Septerna had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $49.00 price target on the stock.
• 8/11/2026 – Septerna was given a new $49.00 price target by Stifel Nicolaus.
• 8/11/2026 – Septerna had its price target raised by Guggenheim from $45.00 to $51.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Septerna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/1/2026 – Septerna had its price target lowered by Guggenheim from $52.00 to $45.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Septerna had its price target raised by Truist Financial Corporation from $35.00 to $43.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Septerna had its “buy” rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.

Insider Buying and Selling at Septerna

In related news, SVP Daniel D. Long sold 3,334 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total value of $114,922.98. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,323,321.64. The trade was a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Samira Shaikhly sold 2,178 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $35.18, for a total value of $76,622.04. Following the transaction, the insider directly owned 793 shares in the company, valued at approximately $27,897.74. The trade was a 73.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 47,828 shares of company stock worth $1,584,314 over the last quarter. 5.80% of the stock is owned by company insiders.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.